Migraine and Endothelial Dysfunction

This study is currently recruiting participants.
Verified June 2011 by Charite University, Berlin, Germany
Sponsor:
Information provided by:
Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT01388699
First received: July 5, 2011
Last updated: July 6, 2011
Last verified: June 2011

July 5, 2011
July 6, 2011
October 2010
August 2011   (final data collection date for primary outcome measure)
Endothelial Microparticles [ Time Frame: baseline ] [ Designated as safety issue: No ]
Levels of endothelial microparticlel in the peripheral blood using flow cytometry
Same as current
Complete list of historical versions of study NCT01388699 on ClinicalTrials.gov Archive Site
  • Levels of circulating Endothelial Progenitor Cells [ Time Frame: baseline ] [ Designated as safety issue: No ]
    Levels of cEPC (CD34+/CD133+/VGF2R/CD31) in % of mononuclear cells using flow cytometry
  • Digital pulse volume change [ Time Frame: baseline ] [ Designated as safety issue: No ]
    Digital pulse volume change (with RH PAT as non invasive measurement (PAT-ratio; ENDOPAT, Itamar Medical Ltd.) for non-invasive, peripheral endothelial function
Same as current
Not Provided
Not Provided
 
Migraine and Endothelial Dysfunction
Migraine and Endothelial Dysfunction

Recently, there is evidence that endothelial activation and dysfunction are associated with migraine, especially in female migraineurs with aura. Our objectives were to determine whether novel endothelial function markers are altered in female migraineurs with aura compared to age-matched controls.

Our objectives were to determine whether novel endothelial function methods and novel markers of endothelial activation are associated with migraine in female migraineurs with aura.

Migraine is an independent risk factor for stroke, especially in young women with aura symptoms. Endothelial dysfunction is a risk factor for cardiovascular diseases. Recent studies suggest that there is a link between migraine with aura and endothelial activation, dysfunction and impaired vascular reactivity.

In this case-control study the investigators examine several novel biomarkers of endothelial function such as endothelial progenitor cells and endothelial microparticles as well as novel methods such as reactive hyperemic peripheral arterial tonometry in female migraineurs with aura and age-matched controls.

Observational
Observational Model: Case Control
Not Provided
Not Provided
Non-Probability Sample

female migraineurs from outpatient clinic

Migraine With Aura
Not Provided
  • migraine group
    female migraineurs with aura
  • control group
    healthy women without headache syndrome
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
September 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • migraine with aura
  • age < 50
  • female gender

Exclusion Criteria:

  • severe infectious disease
  • cardiovascular disease (stroke, coronary heart disease, myocardial infarction)
  • vasculitis
  • peripheral artery disease
  • diabetes mellitus
  • pregnancy
  • drug abuse
  • medication: statin, anticoagulation, aspirin, clopidogrel
  • intake of triptans <24h
Female
18 Years to 50 Years
Yes
Contact: Matthias Endres, MD 004930450560102 matthias.endres@charite.de
Contact: Thomas G Liman, MD 004930450560643 thomas.liman@charite.de
Germany
 
NCT01388699
FF_NCRC_Migraine&ED
No
Center for Stroke Research Berlin, Center for Stroke Research Berlin (Matthias Endres)
Charite University, Berlin, Germany
Not Provided
Principal Investigator: Matthias Endres, MD Center for Stroke Research Berlin, Charité Campus Mitte
Charite University, Berlin, Germany
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP